DexCom, Inc. (DXCM)
NASDAQ: DXCM · IEX Real-Time Price · USD
111.66
+0.96 (0.87%)
At close: Jul 19, 2024, 4:00 PM
111.64
-0.02 (-0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
DexCom Revenue
DexCom had revenue of $3.80B in the twelve months ending March 31, 2024, with 25.78% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $921.00M with 24.21% year-over-year growth. In the year 2023, DexCom had annual revenue of $3.62B with 24.49% growth.
Revenue (ttm)
$3.80B
Revenue Growth
+25.78%
P/S Ratio
11.68
Revenue / Employee
$396,021
Employees
9,600
Market Cap
44.41B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
Dec 31, 2006 | 2.17M | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cencora | 276.54B |
Humana | 109.24B |
Takeda Pharmaceutical | 28.16B |
Becton, Dickinson and Company | 19.72B |
IQVIA Holdings | 15.07B |
Haleon | 14.31B |
Alcon | 9.56B |
Edwards Lifesciences | 6.14B |
DXCM News
- 24 days ago - Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time. - Business Wire
- 4 weeks ago - Dexcom Expands AID Partnership Into The Netherlands - Business Wire
- 4 weeks ago - Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes - Business Wire
- 4 weeks ago - New Weight-Loss Drugs and Devices Are Coming This Week - Barrons
- 6 weeks ago - Dexcom G7 Now Connects Directly to Apple Watch in the U.S. - Business Wire
- 6 weeks ago - Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes - Business Wire
- 6 weeks ago - Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems - Business Wire
- 7 weeks ago - Dexcom Announces Upcoming Conference Presentation - Business Wire